Processing

Please wait...

Settings

Settings

Goto Application

1. WO2002024188 - USE INOS INHIBITORS TO TREAT OR PREVENT MYOPIA

Publication Number WO/2002/024188
Publication Date 28.03.2002
International Application No. PCT/CN2000/000285
International Filing Date 20.09.2000
IPC
A61K 31/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
A61K 31/366 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
335having oxygen as the only ring hetero atom, e.g. fungichromin
365Lactones
366having six-membered rings, e.g. delta-lactones
A61K 31/513 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
513having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
CPC
A61K 31/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
A61K 31/366
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
335having oxygen as the only ring hetero atom, e.g. fungichromin
365Lactones
366having six-membered rings, e.g. delta-lactones
A61K 31/513
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two ; or more; nitrogen atoms as the only ring heteroatoms, e.g. piperazine ; or tetrazines
505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
513having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
Applicants
  • YONG GUANG PHARMACEUTICAL CO., LTD. [CN]/[CN] (AllExceptUS)
  • CHIOU, George, C., Y. [US]/[US] (UsOnly)
  • CHENG, Tricia, T., S. [US]/[US] (UsOnly)
Inventors
  • CHIOU, George, C., Y.
  • CHENG, Tricia, T., S.
Agents
  • CHINA PATENT AGENT (H.K.) LTD.
Priority Data
Publication Language Chinese (ZH)
Filing Language Chinese (ZH)
Designated States
Title
(EN) USE INOS INHIBITORS TO TREAT OR PREVENT MYOPIA
(FR) INHIBITEUR DE LA NO SYNTHETASE INDUCTIBLE (INOS) UTILISE POUR LE TRAITEMENT OU LA PREVENTION DE LA MYOPIE
Abstract
(EN)
The invention relates to the hydrazine derivatives represent by the formula (I) (wherein R1 represents hydrogen, optionally substituted C1-C6 alkyl and the like; m represents a integral of 0 to 2, n represents a integral of 0 to 5; A represents a 5-10 membered mono-or poly-cyclic heterocycle containing 1-4 identical or different heteroatoms selected from N, O and S, or a carbocycle; B represents a aromatic ring), the preparation thereof, the compositions containing the compound as active ingredient, the use of the compound for the production of medicaments for the treatment or prevention of myopia, the method for the treatment and prevention of myopia, and a commercial kit containing the compound and related information. The compounds of the invention show effective effects for the treatment or prevention of myopia.
(FR)
L'invention concerne la formule (I) dans laquelle R1 désigne un hydrogène sélectionné dans le groupe alkyle C1-C6 ; m désigne un nombre entier compris entre O et 2; A désigne entre 5 et 10 mono- ou poly-hétérocycles à chaîne contenant entre 1 et 4 atomes identiques ou différents sélectionnés dans le groupe constitué par N, O et S, ou un cycle carbone ; et B désigne un noyau aromatique. L'invention concerne également un dérivé de diazane, son procédé de préparation, une composition pharmaceutique contenant ledit dérivé, les applications dudit dérivé lors de la préparation de la composition pharmaceutique indiquée pour le traitement ou la prévention de la myopie, les méthodes thérapeutiques et prophylactiques et les comprimés à vendre contenant ce dérivé et les informations associées. Les composés de cette invention sont efficaces dans le traitement et la prévention de la myopie.
Also published as
Latest bibliographic data on file with the International Bureau